Clinical Trial

SLGT2i for Neuroprotection in Patients With Acute Ischemic Stroke

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated August 11, 2025 (before its estimated August 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
Stroke is a leading cause of disability and mortality globally. With population aging, ischemic stroke (80% of cases) has become China's primary cause of adult disability. Sodium-dependent glucose transporters 2 inhibitors （SGLT2i） demonstrate cardiovascular protection beyond glycemic control, even in patients without diabetes. Preclinical studies suggest neuroprotective effects via improving cerebral glucose metabolism, anti-inflammatory/antioxidant actions, and reducing neuronal apoptosis. Therefore, the investigators aim to evaluate whether SGLT2i could improve 3-month functional outcomes (mRS scores) in AIS patients compared to standard care.
Protocol Amendment History 1 change
notable Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University -> Second Affiliated Hospital, Zhejiang University, School of Medicine 2026-08-09
Trial Details
NCT Number NCT07105917
Lead Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions Acute Ischemic Stroke
Enrollment 1,050 participants
Start Date 2025-08-01
Primary Completion 2026-08-01 (estimated)
Study Completion 2026-11-01 (estimated)
Updated on ClinicalTrials.gov 2025-08-11